Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects
Open accessThe DOI matches its Crossref record; 80 of the 83 references it cites were found in a registry or an index.
Abstract
Platinum complexes are clinically used as adjuvant therapy of cancers aiming to induce tumor cell death. Depending on cell type and concentration, cisplatin induces cytotoxicity, e.g., by interference with transcription and/or DNA replication mechanisms. Additionally, cisplatin damages tumors via induction of apoptosis, mediated by the activation of various signal transduction pathways, including calcium signaling, death receptor signaling, and the activation of mitochondrial pathways. Unfortunately, neither cytotoxicity nor apoptosis are exclusively induced in cancer cells, thus, cisplatin might also lead to diverse side-effects such as neuro- and/or renal-toxicity or bone marrow-suppression. Moreover, the binding of cisplatin to proteins and enzymes may modulate its biochemical mechanism of action. While a combination-chemotherapy with cisplatin is a cornerstone for the treatment of multiple cancers, the challenge is that cancer cells could become cisplatin-resistant. Numerous mechanisms of cisplatin resistance were described including changes in cellular uptake, drug efflux, increased detoxification, inhibition of apoptosis and increased DNA repair. To minimize cisplatin resistance, combinatorial therapies were developed and have proven more effective to defeat cancers. Thus, understanding of the biochemical mechanisms triggered by cisplatin in tumor cells may lead to the design of more efficient platinum derivates (or other drugs) and might provide new therapeutic strategies and reduce side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Platinum anticancer drugs, such as cisplatin, the most potent member of the platinum drug family, penetrate into the nucleus of cancer cells and form adducts with DNA leading to apoptosis [4].”
From Co-delivery of Paclitaxel and Cisplatin in Poly(2-oxazoline) Polymeric Micelles: Implications for Drug Loading, Release, Pharmacokinetics and Outcome of Ovarian and Breast Cancer Treatments (2019) · cites this paper as [4]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A., Küçük, Ö., & Sarkar, F. H. (2006) · Cancer · doi:10.1002/cncr.21731 · Cited by 84
RetractedMechanisms of resistance to cisplatin
Kartalou, M., & Essigmann, J. M. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00141-5 · Cited by 869
Lebwohl, D., & Canetta, R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00224-x · Cited by 754
Cellular and molecular pharmacology of oxaliplatin.
Raymond, É., Faivre, S. J., Chaney, S. G., WOYNAROWSKI, J. M., & Cvitkovic, E. (2002) · PubMed · Cited by 576
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy
Hall, M. D., Okabe, M., Shen, D.-W., Liang, X.-J., & Gottesman, M. M. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.080907.180426 · Cited by 474
Molecular mechanisms involved in cisplatin cytotoxicity
Jordan, P., & Carmo-Fonseca*, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000762 · Cited by 398
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Particular aspects of platinum compounds used at present in cancer treatment
Desoize, B., & Madoulet, C. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00219-0 · Cited by 393
Modifications of DNA by platinum complexes
Brabec, V., & Kasparkova, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 373
Pogribny, I. P., Filkowski, J. N., Tryndyak, V. P., Golubov, A., Shpyleva, S. I., & Kovalchuk, O. (2010) · International Journal of Cancer · doi:10.1002/ijc.25191 · Cited by 334
Occurrence, use and potential toxic effects of metals and metal compounds
Florea, A.-M., & Büsselberg, D. (2006) · BioMetals · doi:10.1007/s10534-005-4451-x · Cited by 315
Self-citationNucleic Acid–Metal Ion Interactions
(2008) · Royal Society of Chemistry eBooks · doi:10.1039/9781847558763 · Cited by 265
Brozovic, A., Ambriović-Ristov, A., & Osmak, M. (2010) · Critical Reviews in Toxicology · doi:10.3109/10408441003601836 · Cited by 261
Cisplatin Overdose: Toxicities and Management
Tsang, R. Y., Al-Fayea, T., & Au, H.-J. (2009) · Drug Safety · doi:10.2165/11316640-000000000-00000 · Cited by 235
Metal complexes in medicine with a focus on enzyme inhibition
Che, C.-M., & Siu, F.-M. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.11.015 · Cited by 224
Cellular and molecular aspects of drugs of the future: oxaliplatin
Di Francesco, A. M., Ruggiero, A., & Riccardi, R. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012514 · Cited by 207
Trans-Platinum Complexes in Cancer Therapy
Coluccia, M., & Natile, G. (2007) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152007779314080 · Cited by 202
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202
Sedletska, Y., Giraud-Panis, M.-J., & Malinge, J.-M. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053765967 · Cited by 195
A Pathophysiologic Role for T Lymphocytes in Murine Acute Cisplatin Nephrotoxicity
Liu, M., Chien, C.-C., Burne-Taney, M., Molls, R. R., Racusen, L. C., Colvin, R. B., & Rabb, H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010102 · Cited by 182
Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Chen, D., Milacic, V., Frezza, M., & Dou, Q. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787582183 · Cited by 178
Relationship Between Cisplatin Administration and the Development of Ototoxicity
Rademaker-Lakhai, J. M., Crul, M., Zuur, L., Baas, P., Beijnen, J. H., Simis, Y. J. W., van Zandwijk, N., & Schellens, J. H. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.077 · Cited by 174
Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats
Pratibha, R., Sameer, R., Rataboli, P. V., Bhiwgade, D. A., & Dhume, C. Y. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.007 · Cited by 173
TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Bellail, A., Qi, L., Mulligan, P., Chhabra, V., & Hao, C. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709787047530 · Cited by 161
Mitochondria as targets for chemotherapy
Gogvadze, V. G., Orrenius, S., & Zhivotovsky, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0323-0 · Cited by 140
MicroRNA-34a Is Induced via p53 during Cisplatin Nephrotoxicity and Contributes to Cell Survival
Bhatt, K., Zhou, L., Mi, Q.-S., Huang, S., She, J.-X., & Dong, Z. (2010) · Molecular Medicine · doi:10.2119/molmed.2010.00002 · Cited by 136
Mitochondrial density determines the cellular sensitivity to cisplatin-induced cell death
Qian, W., Nishikawa, M., Haque, A. M., Hirose, M., Mashimo, M., Sato, E. F., & Inoue, M. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00265.2005 · Cited by 133
Cisplatin Resistance and Transcription Factors
Torigoe, T., Izumi, H., Ishiguchi, H., Yoshida, Y., Tanabe, M., Yoshida, T., Igarashi, T., Niina, I., Wakasugi, T., Imaizumi, T., et al. (2005) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011053352587 · Cited by 133
Maffucci, T., Piccolo, E., Cumashi, A., Iezzi, M., Riley, A. M., Saiardi, A., Godage, H. Y., Rossi, C., Broggini, M., Iacobelli, S., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0121 · Cited by 131
New-Generation Platinum Agents for Solid Tumors
Shah, N. A., & Dizon, D. S. (2009) · Future Oncology · doi:10.2217/14796694.5.1.33 · Cited by 126
Targeting of cancer energy metabolism
Rodríguez‐Enríquez, S., Marín‐Hernández, A., Gallardo‐Pérez, J. C., Carreño‐Fuentes, L., & Moreno‐Sánchez, R. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700470 · Cited by 118
Mitochondrial off targets of drug therapy
Wallace, K. B. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.04.001 · Cited by 106
A Better Platinum-Based Anticancer Drug Yet to Come?
Olszewski, U., & Hamilton, G. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010791162306 · Cited by 105
Abbosh, P. H., Montgomery, J. S., Starkey, J. A., Novotny, M., Zuhowski, E. G., Egorin, M. J., Moseman, A. P., Golas, A., Brannon, K. M., Balch, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3575 · Cited by 105
Mitochondria as targets for cancer therapy
Ralph, S. J., & Neuzil, J. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800044 · Cited by 97
Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1450 · Cited by 94
SMC1 coordinates DNA double-strand break repair pathways
Schär, P., Fäsi, M., & Jessberger, R. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh716 · Cited by 89
Splettstoesser, F., Florea, A.-M., & Büsselberg, D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707335 · Cited by 85
Self-citationAnti-cancer drugs interfere with intracellular calcium signaling
Florea, A.-M., & Büsselberg, D. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.04.014 · Cited by 80
Self-citationMuscella, A., Calabriso, N., Fanizzi, F. P., Pascali, S. A. D., Urso, L., Ciccarese, A., Migoni, D., & Marsigliante, S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707576 · Cited by 73
Muscella, A., Calabriso, N., Fanizzi, F. P., Pascali, S. A. D., Urso, L., Ciccarese, A., Migoni, D., & Marsigliante, S. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707646 · Cited by 61
Cisplatin-induced Post-translational Modification of Histones H3 and H4
Wang, D., & Lippard, S. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402547200 · Cited by 60
Hail, N., & Lotan, R. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200700527 · Cited by 60
Park, C.-M., Park, M.-J., Kwak, H.-J., Moon, S.-I., Yoo, D.-H., Lee, H.-C., Park, I.-C., Rhee, C. H., & Hong, S.-I. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.1.119 · Cited by 58
Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Zhang, J., Wang, L., Xing, Z.-Y., Liu, D., Sun, J., Li, X., & Zhang, Y. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010791162270 · Cited by 58
Other Drugs Acting on Nervous System Associated with QT-Interval Prolongation
Keller, G. A., Ponte, M. L., & Girolamo, G. D. (2009) · Current Drug Safety · doi:10.2174/157488610789869256 · Cited by 57
Qiu, Y.-Y., Mirkin, B. L., & Dwivedi, R. S. (2005) · Cancer Detection and Prevention · doi:10.1016/j.cdp.2005.05.004 · Cited by 55
Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats
Tomaszewski, A., & Büsselberg, D. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.07.005 · Cited by 55
Self-citationWang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.1.19 · Cited by 54
Drottar, M., Liberman, M. C., Ratan, R. R., & Roberson, D. W. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000197630.85208.36 · Cited by 50
Xie (2010) · Oncology Reports · doi:10.3892/or_00000813 · Cited by 49
Ganjavi, H., Gee, M. F. W., Narendran, A., Parkinson, N., Krishnamoorthy, M., Freedman, M. H., & Malkin, D. M. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700909 · Cited by 47
TRAIL and Chemotherapeutic Drugs in Cancer Therapy
Wu, X., Ogawa, O., & Kakehi, Y. (2004) · Vitamins and hormones · doi:10.1016/s0083-6729(04)67019-1 · Cited by 46
Cancer and Metals and Metal Compounds:
Desoize, B. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00017-3 · Cited by 46
Shamimi-Noori, S. M., Yeow, W.-S., Ziauddin, M. F., Xin, H., Tran, T.-V., Xie, J., Loehfelm, A., Patel, P. V., Yang, J., Schrump, D. S., et al. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701120 · Cited by 45
Günes, D. A., Florea, A.-M., Splettstoesser, F., & Büsselberg, D. (2008) · NeuroToxicology · doi:10.1016/j.neuro.2008.12.001 · Cited by 42
Self-citationWang, H., Qian, H., Yu, J., Zhang, X., Zhang, L., Fu, M., Liang, X., Zhan, Q., & Chen, L. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.4.2477 · Cited by 41
Ganjavi, H., Gee, M. F. W., Narendran, A., Freedman, M. H., & Malkin, D. M. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700798 · Cited by 41
Basu, S. C., Ma, R., Boyle, P. J., Mikulla, B., Bradley, M., Smith, B. L., Basu, M., & Banerjee, S. (2003) · Glycoconjugate Journal · doi:10.1023/b:glyc.0000043293.46845.07 · Cited by 40
King, M. T., McConkey, C., Latief, T. N., Hartley, A. G. J., & Fernando, I. N. (2005) · Clinical Oncology · doi:10.1016/j.clon.2005.09.001 · Cited by 40
Wang, Z., Miao, X., Tan, W., Zhang, X.-R., Xu, B., & Lin, D. (2004) · PubMed · Cited by 39
Benedetti, M., Ducani, C., Migoni, D., Antonucci, D., Vecchio, V. M., Ciccarese, A., Romano, A., Verri, T., Ciccarella, G., & Fanizzi, F. P. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200703160 · Cited by 34
Xie, X., Yang, D., Ye, Z., & Tao, H. (2006) · Cancer Investigation · doi:10.1080/07357900500449520 · Cited by 30
Hearing Genes and Cisplatin Deafness: A Pilot Study
Knoll, C. M., Smith, R. J., Shores, C. G., & Blatt, J. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000185596.20207.d2 · Cited by 29
Recognition of cisplatin-damaged DNA by p53 protein: Critical role of the p53 C-terminal domain
Pivoňková, H., Brázdová, M., Kašpárková, J., Brabec, V., & Fojta, M. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.038 · Cited by 25
Specific resistance upon lentiviral TRAIL transfer by intracellular retention of TRAIL receptors
Wenger, T., Mattern, J., Penzel, R., Gaßler, N., Haas, T. L., Sprick, M. R., Walczak, H., Krammer, P. H., Debatin, K., & Herr, I. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401867 · Cited by 24
In vitro toxicological evaluation of a dinuclear platinum(II) complex with acetate ligands
Momekov, G., Ferdinandov, D., Bakalova, A. G., Zaharieva, M. M., Konstantinov, S., & Karaivanova, M. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0078-0 · Cited by 24
Masubuchi, Y., Kawasaki, M., & Horie, T. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0079-z · Cited by 23
Basma, H., El-Refaey, H., Sgagias, M. K., Cowan, K. H., Luo, X., & Cheng, P. (2005) · Journal of Biomedical Science · doi:10.1007/s11373-005-9025-y · Cited by 22
Cancer and Metals and Metal Compounds:
Desoize, B. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00039-2 · Cited by 22
Lacy, J., Loomis, R. H., Grill, S. P., Srimatkandada, P., Carbone, R., & Cheng, Y. (2006) · International Journal of Cancer · doi:10.1002/ijc.21804 · Cited by 20
Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies
Garcia, J. A., & Dreicer, R. (2005) · Nature Clinical Practice Urology · doi:10.1038/ncpuro0068 · Cited by 14
Iioka, Y., Mishima, K., Azuma, N., Tsuchida, A., Takagi, Y., Aoki, T., & Saito, I. (2005) · Pathobiology · doi:10.1159/000084119 · Cited by 13
Molecular alterations of cells resistant to platinum drugs: Role of PKCα
Righetti, S. C., Perego, P., Carenini, N., Corna, E., Bo, L. D., Cedrola, S., Porta, C. A. M. L., & Zunino, F. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.12.007 · Cited by 13
[Mechanisms for resistance to anticancer agents and the reversal of the resistance].
Akiyama, S.-I., Chen, Z., Kitazono, M., Sumizawa, T., Furukawa, T., & Aikou, T. (1999) · PubMed · Cited by 12
Hail, N., & Lotan, R. (2009) · Cited by 10
Erythrocyte aminolevulinic acid dehydratase inhibition by cis-platin
Trevisan, A., Borella-Venturini, M., Marco, L. D., Fabrello, A., Giraldo, M., Zanetti, E., Marzano, C., & Fregona, D. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2004.04.015 · Cited by 5
[Oxaliplatin and ovarian cancer].
Dieras, V. C., Girre, V., Guilhaume, M.-N., Laurence, V., & Mignot, L. (2006) · PubMed · Cited by 4
太田, 剛. (2008) · Medical Entomology and Zoology · Cited by 1
Research works printed but not linked: 2
- Chattopadhyay S. Machado-Pinilla R. Manguan-Garcia C. Belda-Iniesta C. Moratilla C. Cejas P. Fresno-Vara J.A. de Castro-Carpeno J. Casado E. Nistal M. Gonzalez-Che C.M. Siu F.M. Metal complexes in medicine with a focus on enzyme inhibition Curr. Opin. Chem. Biol. 2010 14 255 261 20018553 · DOI · Paper page
- Florea A.-M. Büsselberg D. Cisplatin as an anti-tumour drug: Cellular mechanisms of activity, drug resistance and induced side effects Cancers 2011 in press PMC3756417 24212665
Cited by
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
Zhou, Z., Song, J., Nie, L., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00271d · Cited by 2,098
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
Metadata
- Authors
- Florea, A.-M., & Büsselberg, D.
- Affiliations
- Heinrich Heine University Düsseldorf (DE)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Büsselberg, Dietrich
- ORCID
- Büsselberg, Dietrich
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2011-03-15
- Volume
- 3
- Issue
- 1
- Pages
- 1351-1371
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC3756417
- OpenAlex
- W2073131323
- Cited by
- 1,759
- References
- 83
- Citations by year
- 2026: 65 · 2025: 111 · 2024: 154 · 2023: 148 · 2022: 165 · 2021: 177 · 2020: 195 · 2019: 176 · 2018: 133 · 2017: 129 · 2016: 100 · 2015: 82 · 2014: 70 · 2013: 28 · 2012: 21
- FWCI
- 19.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- cisplatin, platinum complexes, apoptosis, DNA replication inhibition, calcium signaling, death receptor signaling, mitochondrial apoptosis, drug resistance, neurotoxicity, nephrotoxicity, myelosuppression, combination chemotherapy, DNA repair, drug efflux, cellular uptake, platinum derivatives
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

